Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery IndustryGlobeNewsWire • 12/20/23
Recursion Pharmaceuticals Wants to 4X Its Supercomputing Power for AI With the Help of Nvidia. Here's Why It Matters.The Motley Fool • 11/26/23
Cathie Wood Just Made a Big Bet on Recursion Pharmaceuticals Stock. Will It Pay Off?The Motley Fool • 11/21/23
Recursion Pharmaceuticals: Second Half 2024 Data Readouts Are Major Inflection PointsSeeking Alpha • 11/16/23
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision OncologyGlobeNewsWire • 11/09/23
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/09/23
1 Artificial Intelligence Stock to Buy Hand Over Fist in October and 1 to AvoidThe Motley Fool • 10/13/23